2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
47
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
13
Sarcoma
9
Lymphoma
6
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Glioblastoma
5
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Non-Hodgkin
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Docetaxel
292
Prednisone
240
enzalutamide
193
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
169
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
92
gallium 68 PSMA-11
81
abiraterone
81
Specimen Handling
73
darolutamide
65
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
52
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
selinexor
×
Clear all
NCT02146833
2023-01-26
SHIP
Karyopharm Therapeutics Inc
Phase 2
Terminated
20 enrolled
13 charts